Hugues Lecat appointed Chairman of the Board of Directors of Guerbet Villepinte, 24 May 2024: Guerbet (FR0000032526 GBT), a global specialist in contrast products and solutions for medical imaging,...
NUCLIDIUM and Guerbet Form Strategic Partnership to Support the Advancement of targeted Copper-based Radiotheranostics -- Agreement brings together Guerbet's industry leading expertise in medical...
Q1 2024 revenue Quarterly activity Revenue: ‚194.3m, up 8.8% at CER1Growth remains particularly strong in Asia (+26.8% at CER) and the Americas (+20.1% at CER); the EMEA region (-6.2% at CER) was...
Financial agenda for 2024 Villepinte, 15 January 2024: Guerbet (FR0000032526), a global specialist in contrast agents and solutions for medical imaging, is announcing its financial agenda for 2024. ...
Revenue at 30 September 2023 Activity 9-month revenue: ‚¬573.9 million, up 2.7% at CER1 Third-quarter sales remained very strong in...
The CHMP issues an opinion in favour of granting an EU marketing authorisation for Elucirem„¢ (Gadopiclenol)with the indication of use for magnetic resonance imaging with contrast enhancement in...
Half-year results 2023 Acceleration of activity Half-year revenue: ‚¬378.6 million, up 2.8% at CER1Strong acceleration of activity in the second quarter, up 6.7% at CER Profitability in...
NEW YORK, July 20, 2023 (GLOBE NEWSWIRE) -- Betterguards, a next-generation sports technology innovator, announced today the unveiling of its newly launched U.S. product The BetterGuard during NBA...
Guerbet wins PI-CAI Grand Challenge on detection of prostate cancer Villepinte, 17 July 2023: Guerbet (FR0000032526 GBT), a global specialist in contrast media and medical imaging solutions, is...